Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 7/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278008 | 0.91 | GCK (0.40) | CASP1ALDH1A1GCKMRGPRX1NPC1 | |
| SCHEMBL14278003 | 0.90 | CASP1 (0.46) | CASP1PKM | |
| SCHEMBL14278006 | 0.90 | CASP1 (0.41) | CASP1TBXA2R | |
| SCHEMBL14278009 | 0.89 | TBXA2R (0.44) | CASP1MRGPRX1TBXA2R | |
| SCHEMBL14278005 | 0.89 | MEN1 (0.39) | CASP1ALDH1A1GCKMRGPRX1F10 | |
| SCHEMBL14364351 | 0.87 | CASP1 (0.40) | CASP1AKR1C3ALDH1A1GCKMRGPRX1 | |
| SCHEMBL14278309 | 0.79 | BCL2L1 (0.48) | — | |
| SCHEMBL14364352 | 0.79 | MMP3 (0.39) | CASP1GCKMRGPRX1NPC1KAT6A | |
| SCHEMBL14364353 | 0.77 | MEN1 (0.38) | CASP1ALDH1A1GCKMRGPRX1F10 | |
| SCHEMBL14364342 | 0.77 | CASP1 (0.40) | CASP1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CASP1 954/4885AKR1C3 367/4885ALDH1A1 135/4885 |
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CASP1 954/4885AKR1C3 367/4885ALDH1A1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.